

V.3 Summary of Risk Minimisation Measures

Not applicable.

Part VI: Summary of the risk management plan

Summary of risk management plan Bladex (folic acid)

This is a summary of the risk management plan (RMP) for Bladex. The RMP details important risks of Bladex, and how more information will be obtained about Bladex' risks and uncertainties (missing information).

Bladex' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Bladex should be used.

I. The medicine and what it is used for

Bladex is authorised for folic acid deficiency or conditions with increased folate need (see SmPC for the full indication).

It contains folic acid as the active substance and it is given orally. The tablets are available in strengths of 1 mg and 5 mg.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Bladex together with measures to minimise such risks and the proposed studies for learning more about Bladex' risks, are outlined below.

Measures to minimize the risks identified for medicinal products are :

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute *routine risk minimization* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Bladex are risks that need special risk management activities to further investigate or

minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Bladex. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

Not applicable, no safety concerns were identified.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Bladex.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Bladex.